Pancreatic Cancer Action Network (PanCAN) grantee George Miller, head of the Cancer Immunology Program at Perlmutter and vice chair for research in the Department of Surgery at NYU Langone and his research team have discovered a novel and potentially targetable way that pancreatic cancer cells hide themselves from the immune system. The findings, published online in the journal Nature Medicine, have the potential to broach a new era of effective immunotherapies for pancreatic cancer.
Terumo Europe NV has announced the first commercial clinical case using Quiremspheres—the next generation radioembolization microspheres for advanced unresectable liver cancer.
Goetz Richter, Clinic for Diagnostic and Interventional Radiology, Stuttgart, Germany, presented breaking data from the Miracle 1 multicentre hepatocellular carcinoma trial at The Symposium on Clinical Interventional Oncology (CIO, 4–5 February, Hollywood, Florida). He spoke to Interventional News on the role of drug-eluting particles in interventional oncology.
“Cryoablation of metastatic breast cancer is a safe and effective method that allows local control of the disease,” Claudio Pusceddu told delegates at the European Congress of Radiology (1–5 March, Vienna, Austria).
In a new study published in JCI Insight, UC Davis researchers have shown that combining high-intensity focused ultrasound with two immunotherapies (a PD-1 checkpoint inhibitor and TLR9 agonist) can produce excellent response rates in mouse models of epithelial cancer. They also found that, for the combination to be effective, immunotherapies must come first.
Angiodynamics has announced it has received CE mark certification for the Solero microwave tissue ablation system. Solero and its accessories are indicated for the ablation of soft tissue during open, laparoscopic or percutaneous procedures. The Solero system is not intended for cardiac use.
“Interventional radiology has always been characterised by its innovative spirit. We are now seeing progress with new procedures being developed to create percutaneous arteriovenous fistulae. I am impatiently awaiting the results of the NEAT (Novel endovascular access trial) study,” Gireesh Mukund Warawdekar, consultant interventional radiologist at several leading hospitals in Mumbai, India, and 2014–16 president of the Indian Society of Vascular and Interventional Radiology (ISVIR), tells Interventional News.
“War (as in turf war) is an emotional word because in wars, people get hurt. I believe we truly care about the patients we serve and the last thing we want is for patients to get hurt. […] By and large, we have found that approaching role extension issues through discussion is preferable to confrontation,” Gregory John Slater, president, The Royal Australian and New Zealand College of Radiologists (RANZCR), tells Interventional News. Slater is a radiologist at Queensland X-Ray, Brisbane, Australia and a visiting medical officer at several private hospitals. He enjoys the outdoors, and like any true blue Aussie, loves throwing a shrimp on the barbie.
QT Vascular has announced that it has entered into an asset purchase option agreement with Medtronic, for the acquisition of the non-drug coated Chocolate PTA.
Peripheral artery disease patients who were treated with an anti-inflammatory steroid injected directly into the tissue surrounding their leg artery showed a significant reduction in inflammatory biomarkers.
The Canadian Interventional Radiology Association (CIRA) Board of Directors has announced the appointment of Daniel Lapointe as CIRA’s new executive director on the association’s website.
Two new sub-analyses from the IN.PACT Global Study of the IN.PACT Admiral in patients with peripheral artery disease have been reported at the annual 2017 Charing Cross Symposium (CX) in London, UK, one of the world’s largest educational meetings specialising in vascular and endovascular disease management.
Positive results from the RANGER SFA trial for Boston Scientific’s Ranger paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter have been presented at the 2017 CX Symposium in London, UK. Data demonstrated that the drug-coated balloon (DCB) exhibited both a high rate of primary patency and freedom from target lesion revascularisation at 12 months, reducing the need for re-interventions to re-establish flow in previously blocked blood vessels.
BD (Becton, Dickinson and company) has definitively agreed to acquire Bard for US$317 per common share in cash and stock, for a total consideration of US$24 billion.
Getinge is proud to announce the launch of the Advanta V12 32mm length balloon expandable covered stent at the Charing Cross International Conference. This is a much needed addition to the Advanta V12 product offering and will allow clinicians additional treatment options for optimal patient outcomes, a press release from the company says.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos